A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to compare the confirmed complete cytogenetic
response of dasatinib with that of imatinib within 12 months after randomization in patients
with newly diagnosed chronic-phase Philadelphia positive chronic myeloid leukemia. The safety
of this treatment will also be studied.